

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Health Technology Evaluation

### Equality impact assessment – Scoping

#### Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266]

The impact on equality has been assessed during this evaluation according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

- It was noted that cyclophosphamide, one of the current treatments for EGPA, can cause infertility. So women of childbearing age potentially face a disproportionate harm from this therapy.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

- The committee will consider whether its recommendations could have a different impact on people protected by the equality legislation than on the wider population.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the stakeholder list been made?

No

**Approved by Associate Director (name): .....**

Richard Diaz...

**Date:** 27 Sept 2024